# MapLight Therapeutics, Inc.: overview MPLT · Nasdaq · CIK 1770069 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mplt.md) · [Financials](/companies/mplt/financials.md) · [Filings](/companies/mplt/filings.md) · [Insiders](/companies/mplt/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(25.08)](/filings/0001193125-25-307453.md) | not reported | [(29.33)](/filings/0001193125-26-224129.md) | [(39.11)](/filings/0001193125-26-349554.md) | [(37.18)](/filings/0001193125-25-307453.md) | not reported | [(1.34)](/filings/0001193125-26-224129.md) | [(1.32)](/filings/0001193125-26-349554.md) | | Free cash flow | $m | not reported | [(21.6) d](/filings/0001193125-26-125072.md) | not reported | not reported | [(31.8) d](/filings/0001193125-25-307453.md) | [(47.2) d](/filings/0001193125-26-125072.md) | [(51.2)](/filings/0001193125-26-224129.md) | [(44.9) d](/filings/0001193125-26-349554.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | not reported | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | not reported | not reported | | Net margin | % | not reported | not reported | | Diluted EPS | $ per share | [(105.38)](/filings/0001193125-26-125072.md) | [(18.56)](/filings/0001193125-26-125072.md) | | Free cash flow | $m | [(79.6)](/filings/0001193125-26-125072.md) | [(139)](/filings/0001193125-26-125072.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mplt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NOVO HOLDINGS A/S](/funds/1388325.md) | 2026-06-30 | $132.1m | 3,686,622 | | Unchanged | | [FCPM III SERVICES B.V.](/funds/2013410.md) | 2026-06-30 | $115.6m | 3,226,400 | | Unchanged | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $69.8m | 1,948,312 | | Reduced −46,561 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $36.7m | 1,025,134 | | Reduced −314,597 | | [Nan Fung Group Holdings Ltd](/funds/1782539.md) | 2026-06-30 | $34.8m | 971,253 | | Unchanged | | [5AM Venture Management, LLC](/funds/1799883.md) | 2026-06-30 | $34.0m | 950,011 | | Unchanged | | [Sanofi](/funds/1121404.md) | 2026-06-30 | $32.7m | 912,041 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $30.5m | 852,150 | | Added +513,034 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $29.5m | 823,556 | | Added +619,055 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $28.1m | 784,150 | | Added +64,330 | ## Recent filings [All 209 filings](/companies/mplt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-18 | 20:15 ET | [S-1/A](/filings/0001193125-26-395559.md) | Registration statement, amended | 0001193125-26-395559 | | 2026-09-09 | 21:28 ET | [S-1](/filings/0001193125-26-386648.md) | Registration statement | 0001193125-26-386648 | | 2026-08-18 | 22:51 ET | [SCHEDULE 13D/A](/filings/0001104659-26-098444.md) | Ownership report, active investor, amended | 0001104659-26-098444 | | 2026-08-13 | 21:01 ET | [10-Q](/filings/0001193125-26-349554.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349554 | | 2026-08-13 | 20:51 ET | [8-K](/filings/0001193125-26-349490.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-349490 | | 2026-08-03 | 01:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-089960.md) | Ownership report, active investor, amended | 0001104659-26-089960 | | 2026-07-31 | 13:25 ET | [SCHEDULE 13D/A](/filings/0001388325-26-000034.md) | Ownership report, active investor, amended | 0001388325-26-000034 | | 2026-07-27 | 11:07 ET | [8-K](/filings/0001193125-26-316820.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-316820 | | 2026-06-24 | 11:12 ET | [8-K](/filings/0001193125-26-280243.md) | 5.07 Shareholder vote results | 0001193125-26-280243 | | 2026-06-22 | 11:08 ET | [8-K](/filings/0001193125-26-276691.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-276691 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-125072.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1770069 - Tickers: MPLT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.